Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.
Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected
Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue guidance down 5%,
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.
Lilly forecasts weak sales of weight-loss drug in fourth quarter
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
JD Supra1d
Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Hosted on MSN2d
Eli Lilly: 4 Reasons Investors Shouldn't Miss This Opportunity
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
BioSpace13d
Lilly Asks to Join GLP-1 Compounding Lawsuit
Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome ...
조선일보1d
Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2
Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...
Benzinga.com13d
3LLY : Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks
Eli Lilly intervenes in lawsuit to defend FDA's shortage determination of tirzepatide injections, branded as Mounjaro and Zepbound. FDA allows compounding of tirzepatide injections until ...
BioSpace2d
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Yahoo Finance2d
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...
Eli Lilly cuts FY24 revenue view to ~$45B from $45.4B-$46B, consensus $45.55B
While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration ...
GlobalData on MSN1d
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m
Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.